Repligen Corporation (RGEN)

Repligen's stock price has experienced fluctuations over the past six months. As of March 24, 2026, the share price was $116.30, representing an 18.07% decline from March 25, 2025. Key events impacting the stock include Q4 and full-year 2025 financial results, Q3 and Q2 2025 financial results, a leadership change with Dr. Martin D. Madaus elected as Chair, new product launches of high-performance chromatography resins, and analyst ratings with an average price target of $179.00.

Repligen's business is influenced by the global demand for biologic drugs. Management expects a "normal seasonality split" for 2026, with approximately 48% of revenue in the first half of the year, and Q4 is generally anticipated to be the strongest revenue and margin quarter. The increasing number of biologic drugs in development and on the market drives demand for Repligen's products, indicating a generally growing demand trend rather than strong seasonal fluctuations.

Repligen Corp. is a global life sciences company focused on bioprocessing technologies and systems to enhance the manufacturing of biological drugs. It operates in the healthcare sector, specifically in biotechnology and pharmaceuticals, with a focus on medical instruments and supplies. The company's product portfolio includes filtration, chromatography, process analytics, and proteins, serving a wide range of biologics such as monoclonal antibodies, antibody-drug conjugates, and cell and gene therapies. Filtration products account for approximately 55% of total revenue, chromatography contributes about 21%, process analytics accounts for approximately 13%, and proteins make up about 11% of total revenue.

Repligen has a significant global presence, with its headquarters in Waltham, Massachusetts, and operates across 22 sites globally, including manufacturing facilities and offices in the United States, Europe, and Asia Pacific. Its primary warehouse and distribution centers are located in Massachusetts and California. North America, Europe, and Asia Pacific are key geographic regions, contributing approximately 44%, 37%, and 19% of revenue, respectively.

Repligen is recognized as a global life sciences company specializing in bioprocessing technologies, known for innovation and expertise since 1981. The company is a technology leader in perfusion, pre-packed columns, and integrated systems for tangential flow filtration. Its reputation has been supported by strong financial performance, strategic acquisitions and partnerships, and new product launches. However, material weaknesses in internal control and a gene therapy headwind indicate areas for improvement or challenges.

Repligen's ownership is predominantly held by institutional investors, with institutions collectively owning approximately 101.91% of the company's shares as of January 2025. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, and Price T Rowe Associates Inc. Individual and retail investors also form a significant portion of the shareholder base, comprising about 40.15% of the ownership as of January 2025. Insider ownership remains a small percentage. Bvf Partners L P is the largest individual Repligen shareholder, owning 11.06 million shares.